# Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

> **NCT07027124** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 40 (estimated)

## Conditions studied

- Prostate Cancer
- High-risk Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Pembrolizumab
- **DRUG:** Lupron

## Key facts

- **NCT ID:** NCT07027124
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2026-12-01
- **Final completion:** 2031-05-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07027124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07027124, "Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07027124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*